Patents by Inventor Kjeld Madsen

Kjeld Madsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1 compounds
    Patent number: 9920106
    Abstract: Novel GLP-1 compounds and their therapeutic use.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: March 20, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Jesper Lau, Kjeld Madsen, Thomas Kruse Hansen, Jeppe Sturis
  • Truncated GLP-1 derivatives and their therapeutical use
    Patent number: 9657079
    Abstract: The invention relates to truncated GLP-1 analogs, in particular a GLP-1 analog which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogs and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: May 23, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Janos T. Kodra, Kjeld Madsen, Patrick W. Garibay, Jacob Kofoed, Steffen Reedtz-Runge, Ingrid Pettersson
  • Novel GLP-1 Derivatives
    Publication number: 20160108102
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: June 25, 2015
    Publication date: April 21, 2016
    Inventors: Jesper Lau, Thomas K. Hansen, Kjeld Madsen, Paw Bloch, Florencio Z. Dorwald, Niels L. Johansen
  • Polypeptide protracting tags
    Patent number: 9061067
    Abstract: The invention relates to methods for increasing the plasma half-life of a molecule, such as human growth hormone, comprising covalently linking the molecule to a heterocyclic carboxylic acid bioisostere.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: June 23, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dörwald, Christine Bruun Schiødt, Thomas Kruse Hansen, Kjeld Madsen
  • Acylated exendin-4 compounds
    Patent number: 9012398
    Abstract: This invention provides Exendin-4 compounds derivatized at a lysine 14 residue to give an acylated lysine, pharmaceutical compositions comprising such compounds, and the use of such compositions for treating diabetes.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: April 21, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas K. Hansen, Leif Christensen, Kjeld Madsen, Lauge Schaeffer, Jane Spetzler
  • Truncated GLP-1 Derivatives and Their Therapeutical Use
    Publication number: 20140296131
    Abstract: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.
    Type: Application
    Filed: June 9, 2014
    Publication date: October 2, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Janos T. Kodra, Kjeld Madsen, Patrick W. Garibay, Jacob Kofoed, Steffen Reedtz-Runge, Henning Thoegersen, Ingrid Pettersson
  • Novel GLP-1 Derivatives
    Publication number: 20130244931
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: May 28, 2013
    Publication date: September 19, 2013
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Niels Langeland Johansen
  • GROWTH HORMONE CONJUGATES
    Publication number: 20130143815
    Abstract: The present invention relates to growth hormone conjugates comprising a bile acid residue, said conjugation may occur through wt or mutant amino acid residues. The growth hormone polypeptide may be wt human growth hormone or a growth hormone variant.
    Type: Application
    Filed: July 15, 2011
    Publication date: June 6, 2013
    Applicant: NOVO NORDISK HEALTH CARE AG
    Inventors: Henrik Sune Andersen, Kjeld Madsen, Helle Demuth, Christine Bruun Schioedt, Leif Noerskov-Lauritsen, Peter Thygesen, Carsten Behrens, Mette Guldbrandt
  • NOVEL GLP-1 DERIVATIVES
    Publication number: 20130053315
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: March 22, 2012
    Publication date: February 28, 2013
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
  • ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG
    Publication number: 20130040884
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: March 22, 2012
    Publication date: February 14, 2013
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
  • Acylated GLP-1 Compounds
    Publication number: 20120295847
    Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Application
    Filed: March 5, 2012
    Publication date: November 22, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Florencio Zaragoza Dörwald, Henrik Stephensen, Paw Bloch, Thomas Kruse Hansen, Kjeld Madsen
  • NOVEL GLP-1 COMPOUNDS
    Publication number: 20120289453
    Abstract: Novel GLP-1 compounds and their therapeutic use.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 15, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Jesper Lau, Kjeld Madsen, Thomas Kruse Hansen, Jeppe Sturis
  • Acylated Exendin-4 Compounds
    Publication number: 20120283170
    Abstract: This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.
    Type: Application
    Filed: May 1, 2012
    Publication date: November 8, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen, Leif Christensen, Kjeld Madsen, Lauge Schaeffer, Jane Spetzler
  • Polypeptide Protracting Tags
    Publication number: 20120088716
    Abstract: Method for increasing half-life of compounds in plasma and novel derivatives of such compounds.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 12, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dörwald, Christine Bruun Schiødt, Thomas Kruse Hansen, Kjeld Madsen
  • Derivatives of GLP-1 analogs
    Patent number: 8097698
    Abstract: The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.
    Type: Grant
    Filed: November 26, 2007
    Date of Patent: January 17, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Liselotte Bjerre Knudsen, Per Olaf Huusfeldt, Per Franklin Nielsen, Niels C. Kaarsholm, Helle Birk Olsen, Soren Erik Bjorn, Freddy Zimmerdahl Pedersen, Kjeld Madsen
  • Modification of Factor VIII
    Publication number: 20110306551
    Abstract: A Factor VIII derivative of formula (I): wherein: B represents C2 to C10 alkylene; m represents 0 or an integer from 1 to 19, n represents an integer from 1 to 20, and the sum of m and n is from 1 to 20; P represents a mono or polyradical of Factor VIII obtained by removing m+n carbamoyl groups from the side chains of glutamine residues in Factor VIII; and M represents a moiety (M1) that increases the plasma half-life of the Factor VIII derivative or a reporter moiety (M2); or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 18, 2010
    Publication date: December 15, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Magali Zundel, Bernd Peschke, Ditte Maria Karpf, Kjeld Madsen
  • GLP-1 Derivatives II
    Publication number: 20110053839
    Abstract: The present invention relates to a derivative of GLP-1(7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue.
    Type: Application
    Filed: August 23, 2010
    Publication date: March 3, 2011
    Applicant: NOVO NORDISK A/S
    Inventors: LISELOTTE BJERRE KNUDSEN, PER OLAF HUUSFELDT, PER FRANKLIN NIELSEN, KJELD MADSEN
  • Novel GLP-1 Derivatives
    Publication number: 20100305032
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: May 5, 2010
    Publication date: December 2, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
  • TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE
    Publication number: 20100292133
    Abstract: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.
    Type: Application
    Filed: September 5, 2008
    Publication date: November 18, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, János Tibor Kodra, Kjeld Madsen, Patrick William Garibay, Jacob Kofoed, Steffen Reedtz-Runge, Henning Thøgersen, Igrid Pettersson
  • Acylated Exendin-4 Compounds
    Publication number: 20090318353
    Abstract: This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.
    Type: Application
    Filed: August 24, 2007
    Publication date: December 24, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen, Leif Christensen, Kjeld Madsen, Lauge Schäffer, Jane Spetzler